Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Maxcyte Inc
(NQ:
MXCT
)
4.350
+0.230 (+5.58%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Maxcyte Inc
< Previous
1
2
Next >
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
August 06, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
July 09, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
May 29, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
May 22, 2024
Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T...
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
May 07, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
April 10, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
April 02, 2024
Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
March 12, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
March 04, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
February 09, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
January 30, 2024
Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
January 23, 2024
Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer...
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
January 08, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
January 03, 2024
Lion TCR to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid tumors and viral-related diseases.
From
MaxCyte, Inc; Lion TCR
Via
GlobeNewswire
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
January 02, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
December 11, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
November 16, 2023
MaxCyte continues supporting the advancement of novel therapeutics and looks to support education and advancement of mRNA medicines
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
November 08, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Participate in Two Upcoming Investor Conferences
November 06, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
October 04, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
September 06, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Participate in Baird Global Healthcare Conference
September 05, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
August 09, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
August 01, 2023
Prime Medicine to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance their innovative Prime Editing technology and develop a new class of one-time, potentially curative...
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
July 13, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
July 10, 2023
MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support Vittoria’s Senza5™ technology to enhance efficacy and improve clinical utility of T-cell therapies.
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Lyell Immunopharma
July 06, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Participate in Upcoming Investor Conferences
June 01, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
May 10, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
May 04, 2023
Walking Fish to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases
From
MaxCyte, Inc
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.